Spots Global Cancer Trial Database for Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Official Title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTED LOCALLY ADVANCED OR METASTATIC CANCERS
Study ID: NCT02315066
Conditions
Study Description
Brief Summary: To assess the safety and tolerability at increasing dose levels of PF-04518600 alone or in combination wtih PF-05082566 in patients with select advanced or metastatic carcinoma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Angeles Clinic And Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States
Keck Hospital of USC, Los Angeles, California, United States
LAC+USC Medical Center, Los Angeles, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Ronald Regan Medical Center, Los Angeles, California, United States
UCLA Hematology & Oncology Clinic, Los Angeles, California, United States
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
Medical Imaging Center of Southern California, Inc., Santa Monica, California, United States
Santa Monica UCLA Hematology & Oncology Clinic, Santa Monica, California, United States
UConn Health, Pharmacy, Farmington, Connecticut, United States
UConn Health, Neag Comprehensive Cancer Center, Farmington, Connecticut, United States
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Massachusetts General Hospital (MGH), Boston, Massachusetts, United States
Brigham & Women's Hospital (BWH), Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States
Dana-Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
Massachusetts General/Chelsea HealthCare Center, Chelsea, Massachusetts, United States
Mass General/North Shore Center for Outpatient Care, Danvers, Massachusetts, United States
Mass General West, Waltham, Massachusetts, United States
Columbia University Medical Center - Herbert Irving Pavilion, New York, New York, United States
Methodist Hospital-Pathology, Houston, Texas, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
University of Washington Medical Center, Seattle, Washington, United States
Groupe hospitalier Pitie Salpetriere, Paris, , France
Institut Gustave Roussy, Villejuif, , France
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
The Netherlands Cancer Institute, Amsterdam, , Netherlands
Slotervaart Hospital/Antoni van Leeuwenhoek, Amsterdam, , Netherlands
Erasmus MC, Rotterdam, , Netherlands
Contact Details
Name: Pfizer CT.gov Call Center
Affiliation: Pfizer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
